{"filing":{"accession_number":"0001062993-26-003691","cik":"0001833141","ticker":"HELP","company_name":"CYBIN INC.","form":"6-K","filing_date":"2026-07-16","report_date":null,"primary_document":"form6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1833141/000106299326003691/form6k.htm"},"events":[{"id":18371,"run_id":16513,"accession_number":"0001062993-26-003691","anchor_item_number":"EX-99.1","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"The exhibit discloses an underwritten offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million, closed on June 25, 2026. This is a registered public offering of equity securities under Form F-10 (a multijurisdictional disclosure system filing), not an unregistered private placement. However, the core event—issuance of a substantial number of new common shares to raise capital—is a dilutive equity issuance material to investors. The offering was announced June 24 and closed June 25, 2026, with proceeds intended for clinical development programs (HLP003, HLP004, HLP005) and working capital.","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-07-16","form":"6-K","submitted_at":null,"items":[{"id":17165,"accession_number":"0001062993-26-003691","item_number":"EX-99.1","item_title":"exhibit99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The exhibit discloses an underwritten offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million, closed on June 25, 2026. This is a registered public offering of equity securities under Form F-10 (a multijurisdictional disclosure system filing), not an unregistered private placement. However, the core event—issuance of a substantial number of new common shares to raise capital—is a dilutive equity issuance material to investors. The offering was announced June 24 and closed June 25, 2026, with proceeds intended for clinical development programs (HLP003, HLP004, HLP005) and working capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-16T19:18:08.394953+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17165,"accession_number":"0001062993-26-003691","item_number":"EX-99.1","item_title":"exhibit99-1.htm","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The exhibit discloses an underwritten offering of 10,309,280 common shares at US$4.85 per share for aggregate gross proceeds of US$50 million, closed on June 25, 2026. This is a registered public offering of equity securities under Form F-10 (a multijurisdictional disclosure system filing), not an unregistered private placement. However, the core event—issuance of a substantial number of new common shares to raise capital—is a dilutive equity issuance material to investors. The offering was announced June 24 and closed June 25, 2026, with proceeds intended for clinical development programs (HLP003, HLP004, HLP005) and working capital.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-16T19:18:08.394953+00:00","company_name":"CYBIN INC.","ticker":"HELP","filing_date":"2026-07-16"}]}